Skip to main content
. 2023 Jul 2;7(18):5304–5313. doi: 10.1182/bloodadvances.2023010052

Table 2.

Frequencies and proportions of clinical and biological factors, by sCD163 below or above median (3112 ng/mL)

sCD163
low
n = 65, n (%)
sCD163
high
n = 66, n (%)
P value
Number of events Died 11 (24) 34 (76)
Relapsed 21 (33) 42 (67)
Time of sample Diagnosis 39 (48) 42 (52) .8
Relapse 26 (52) 24 (48)
Age median (range) 69 (46-85) 67 (45-82) .8
Sex Female 17 (47) 19 (53) .7
Male 48 (51) 47 (49)
ECOG 0-1 40 (48) 43 (52) .2
2-4 0 (0) 3 (100)
Unknown 25 20
MIPI 1 14 (67) 7 (33) .2
2 27 (52) 25 (48)
3 23 (43) 31 (57)
Unknown 1 3
LDH Normal 45 (64) 25 (36) <.001
High 19 (33) 38 (67)
Unknown 1 3
Hb Normal 46 (66) 24 (34) <.001
Low 15 (28) 39 (72)
Unknown 4 3
Ki-67 <30 13 (48) 14 (52) .7
≥30 22 (54) 19 (46)
Unknown 30 33
Histology Classic 28 (54) 24 (46) .9
Blastoid 9 (56) 7 (44)
Unknown 28 35
TP53/p53 Low or no mutation 36 (59) 25 (41) .015
High or mutated 4 (25) 25 (75)
Unknown 25 29

High sCD163 was more common in patients with high LDH, low Hb and p53 high/TP53 positive tumors.

ECOG, ECOG performance status scale; LDH, lactate dehydrogenase; MIPI, mantle cell lymphoma international prognostic index.

Data are presented as number (percentage), unless otherwise indicated.

Boldface indicates statistically significant values.

Pearson χ2 test.

Wilcoxon rank sum test.

Fisher exact test.